BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33259901)

  • 1. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
    Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
    Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted liposomal drug delivery: a nanoscience and biophysical perspective.
    Liu Y; Castro Bravo KM; Liu J
    Nanoscale Horiz; 2021 Feb; 6(2):78-94. PubMed ID: 33400747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.
    Gabizon A; Ohana P; Amitay Y; Gorin J; Tzemach D; Mak L; Shmeeda H
    Cancer Drug Resist; 2021; 4(2):463-484. PubMed ID: 35582027
    [No Abstract]   [Full Text] [Related]  

  • 5. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
    Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
    Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil
    Aldughaim MS; Muthana M; Alsaffar F; Barker MD
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33379361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premature Drug Release from Polyethylene Glycol (PEG)-Coated Liposomal Doxorubicin
    Chen E; Chen BM; Su YC; Chang YC; Cheng TL; Barenholz Y; Roffler SR
    ACS Nano; 2020 Jul; 14(7):7808-7822. PubMed ID: 32142248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of RGD-targeted and non-targeted liposomal Galbanic acid on the therapeutic efficacy of pegylated liposomal doxorubicin: From liposomal preparation to in-vivo studies.
    Nik ME; Jaafari MR; Mashreghi M; Nikoofal-Sahlabadi S; Amin M; Sadeghnia HR; Iranshahi M; Navashenaq JG; Malaekeh-Nikouei B
    Int J Pharm; 2021 Jul; 604():120710. PubMed ID: 34019972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the concentration process on unloaded and doxorubicin loaded liposomal dispersions.
    Perinelli DR; Cespi M; Rendina F; Bonacucina G; Palmieri GF
    Int J Pharm; 2019 Apr; 560():385-393. PubMed ID: 30802548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer.
    Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y
    J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice.
    Wang H; Zheng M; Gao J; Wang J; Zhang Q; Fawcett JP; He Y; Gu J
    Talanta; 2020 Feb; 208():120358. PubMed ID: 31816795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking Drugs and Lipids: Quantitative Mass Spectrometry Imaging of Liposomal Doxorubicin Delivery and Bilayer Fate in Three-Dimensional Tumor Models.
    Lopez A; Holbrook JH; Kemper GE; Lukowski JK; Andrews WT; Hummon AB
    Anal Chem; 2024 Jun; 96(22):9254-9261. PubMed ID: 38778440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
    Moles E; Howard CB; Huda P; Karsa M; McCalmont H; Kimpton K; Duly A; Chen Y; Huang Y; Tursky ML; Ma D; Bustamante S; Pickford R; Connerty P; Omari S; Jolly CJ; Joshi S; Shen S; Pimanda JE; Dolnikov A; Cheung LC; Kotecha RS; Norris MD; Haber M; de Bock CE; Somers K; Lock RB; Thurecht KJ; Kavallaris M
    Sci Transl Med; 2023 May; 15(696):eabm1262. PubMed ID: 37196067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasound-mediated delivery enhances therapeutic efficacy of MMP sensitive liposomes.
    Olsman M; Sereti V; Andreassen K; Snipstad S; van Wamel A; Eliasen R; Berg S; Urquhart AJ; Andresen TL; Davies CL
    J Control Release; 2020 Sep; 325():121-134. PubMed ID: 32621827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.
    Islam MR; Patel J; Back PI; Shmeeda H; Adamsky K; Yang H; Alvarez C; Gabizon AA; La-Beck NM
    Nanotheranostics; 2022; 6(4):451-464. PubMed ID: 36105861
    [No Abstract]   [Full Text] [Related]  

  • 16. Direct and simultaneous determination of intra-liposomal and external sulfate in liposomal doxorubicin formulations by capillary electrophoresis/inductively coupled plasma-tandem mass spectrometry (CE/ICP-MS/MS).
    Ansar SM; Mudalige T
    Int J Pharm; 2019 Apr; 561():283-288. PubMed ID: 30844422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
    Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR
    Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review.
    Riaz MK; Riaz MA; Zhang X; Lin C; Wong KH; Chen X; Zhang G; Lu A; Yang Z
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29315231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity.
    Gkionis L; Campbell RA; Aojula H; Harris LK; Tirella A
    Int J Pharm; 2020 Nov; 590():119926. PubMed ID: 33010397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.
    Aloss K; Hamar P
    Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.